Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014;58(2):1243-7.
doi: 10.1128/AAC.02112-13. Epub 2013 Dec 9.

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States

Rodrigo E Mendes  1 , Robert K Flamm, Patricia A Hogan, James E Ross, Ronald N Jones
Affiliations
Multicenter Study

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States

Rodrigo E Mendes et al. Antimicrob Agents Chemother. 2014.

Abstract

This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at ≤2 μg/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.

PubMed Disclaimer

References

    1. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54:621–629. 10.1093/cid/cir895 - DOI - PubMed
    1. Shorr AF, Kunkel MJ, Kollef M. 2005. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56:923–929. 10.1093/jac/dki355 - DOI - PubMed
    1. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34:1481–1490. 10.1086/340353 - DOI - PubMed
    1. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49:2260–2266. 10.1128/AAC.49.6.2260-2266.2005 - DOI - PMC - PubMed
    1. Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2012. LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn. Microbiol. Infect. Dis. 74:54–61. 10.1016/j.diagmicrobio.2012.05.012 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources